Lawrence Lamb | Executive Vice President And Chief Scientific Officer
Incysus Therapeutics

Lawrence Lamb, Executive Vice President And Chief Scientific Officer, Incysus Therapeutics

Dr. Lamb is scientific co-founder, Executive Vice President, and Chief Scientific Officer of Incysus Therapeutics.  As a transplant immunologist with 27 years’ experience in clinical-translational immunotherapy research, he is responsible for first describing the association between relapse-free survival and homeostatic T cell recovery in patients with high-risk leukemia following haploidentical bone marrow transplant. While at the University of Alabama at Birmingham, Dr. Lamb developed the scientific support for chemotherapy resistant T cell-based immunotherapy for high-grade brain tumors that that has become the foundation of our clinical programs.  Dr. Lamb currently leads clinical, translational, and manufacturing strategy and operations for Incysus Therapeutics.


Conference Day 2 - Wednesday 1st April 2020 @ 12:40

Genetic engineering of drug-resistant gamma delta T cells for eradication of residual glioblastoma

  • Haploidentical gamma delta post-transplant immune “boost” and strategy for off the shelf therapy in glioblastoma trial
  • Drug Resistant Immunotherapy (DRI) - gamma delta T cells in combination with chemotherapy – allows superior targeting of residual glioblastoma.
  • Accrual and logistical information from ongoing trials.
last published: 04/Jun/20 08:25 GMT

back to speakers